Mercado Global de Biossimilares – Tendências da Indústria e Previsão para 2030

Análise e dimensão do mercado biossimilar

O número crescente de proficiências em investigação e desenvolvimento levou ao aumento da disponibilidade de biossimilares. Além disso, o aumento do foco da administração de alimentos e medicamentos na melhoria da penetração dos Biossimilares está a ajudar ainda mais o mercado a expandir as suas raízes.

A Data Bridge Market Research analisa que o mercado global de biossimilares, que foi de 37.270,20 milhões de dólares em 2022, deverá atingir os 343.520,90 milhões de dólares até 2030, e deverá passar por um CAGR de 32,00% durante o período de previsão 2023-2030. A “oncologia” domina o segmento de produtos do mercado global de biossimilares devido ao aumento do número de estudos de investigação, ao aumento das atividades de investigação e desenvolvimento dos principais players focados na oncologia e aos avanços nas tecnologias de saúde. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado biossimilar

Market Definition

Biosimilar or follow-on-biologics that are almost an identical copy of an original product but however, is manufactured by another company. Biosimilar is used to treat a wide range of chronic and acute diseases and disorders. Biosimilar is are used to record electrical action produced by the human brain.

Biosimilar Market Dynamics

Drivers

• The Rise in the Prevalence of Diseases

 Surging prevalence of chronic and acute diseases all around the globe owing to various internal and external factors is one of the major factors responsible for fostering growth of the market. Rising patient pool especially in the developing economies coupled with growing cases of Hodgkin's lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis is carving the way for the growth of the market.

• Research and Development Proficiencies

Rising expenditure for research and development proficiencies especially in the developed and developing economies pertaining to the medical instruments and devices will further create lucrative market growth opportunities. Research and development proficiencies have led to the advancements in the medical technology and have improved the quality of healthcare facilities.  Increasing number of screening tests for research proficiencies has further widened the scope of growth.

• Government Investments on Healthcare Infrastructure

The increase in the funding by the federal government is set to drive the growth of the market. Moreover, growth and expansion of healthcare industry being driven by both public and private players especially in the developing economies will create lucrative personal health devices market growth opportunities. Also, growing acceptance of bioidentical hormones replacement therapy by the governmental healthcare facilities is also bolstering the market growth rate.

Opportunity

• Rising Demand for Biologic Drugs

The increasing prevalence of chronic diseases and the growing aging population have led to a rise in the demand for biologic drugs. Biosimilar can help meet this demand and improve patient access to these essential treatments.

Restraint/Challenge

• Regulatory Hurdles

Developing and gaining regulatory approval for biosimilar involves complex and stringent regulatory pathways. Manufacturers need to demonstrate similarity to the reference biologic through comprehensive analytical and clinical studies, which can be time-consuming and costly.

This global biosimilar market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the biosimilar market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• Em julho de 2020, a FDA aprovou o biossimilar de adalimumabe, Hulio, desenvolvido pela Fujifilm Kyowa Kirin Biologics, que está indicado para o tratamento subcutâneo da artrite reumatoide , artrite idiopática juvenil, artrite psoriática , espondilite anquilosante , doença de Crohn em adultos, colite ulcerativa e placas.
•  Em maio de 2020, a Fresenius Kabi recebeu a aceitação das submissões regulamentares para a sua proposta de biossimilar de pegfilgrastim (MSB11455) pela Agência Europeia de Medicamentos (EMA) e pela Food and Drug Administration (FDA) dos EUA, respetivamente.

Âmbito global do mercado biossimilar

O mercado global de biossimilares está segmentado com base no tipo de produto, classe de medicamento, tipo de fabrico, procedimento, doença, indicação, tipo de terapia e utilizadores finais. O crescimento entre estes segmentos irá ajudá-lo a analisar os escassos segmentos de crescimento nas indústrias e fornecer aos utilizadores uma valiosa visão geral do mercado e insights de mercado para os ajudar a tomar decisões estratégicas para identificar as principais aplicações do mercado.

Tipo de produto

• Scanners de ressonância magnética
• Scanners de tomografia computadorizada
• Scanners de tomografia por emissão de posição
• Biossimilar (EEG)
• Dispositivos de eletromiografia (EMG)
• Dispositivos Magnetoencefalográficos
• Dispositivos Doppler Transcranianos
• Monitores de pressão intracraniana (PIC)
• Eletrodos
• Sensores
• Géis
• Cabos

Classe de drogas

• Insulina
• Hormona de Crescimento Humano Recombinante (RHGH)
• Fator estimulador de colónias de granulócitos
• Interferon
• Eritropoetina
• Etanercepte
• Anticorpos Monoclonais
• Folitropina
• Glucagon
• Calcitonina
• Teriparatida
• Enoxaparina Sódica

Tipo de Fabrico

• Fabricação Interna

• Fabrico por contrato

Procedimento

• Invasivo

• Não invasivo

Doença

• Golpe

• Demência

• Epilepsia

Indicação

• Defeito do Septo Atrial (CIA)

• Defeito do Septo Ventricular (CIV)

• Forame Oval Patente (FOP)

• Estenose da Válvula Aórtica
• Outros

Tipo de terapia

• Oncologia

• Imunologia
• Hematologia
• Terapia Hormonal
• Distúrbios metabólicos
• Outros

Utilizadores finais

• Hospitais

• Clínicas
• Centros de diagnóstico
• Outros

Análise/perspetivas regionais do mercado biossimilar

O mercado global de biossimilares é analisado e são fornecidos insights e tendências do tamanho do mercado por país, tipo de produto, classe de medicamentos, tipo de fabrico, procedimento, doença, indicação, tipo de terapia e utilizadores finais, conforme mencionado acima.

Os países abrangidos no relatório global do mercado biossimilar são os EUA, Canadá e México na América do Norte, Alemanha, França, Reino Unido, Holanda, Suíça, Bélgica, Rússia, Itália, Espanha, Turquia, Resto da Europa na Europa, China, Japão , Índia , Coreia do Sul, Singapura, Malásia, Austrália, Tailândia, Indonésia, Filipinas, Resto da Ásia-Pacífico (APAC) na Ásia-Pacífico (APAC), Arábia Saudita, Emirados Árabes Unidos, África do Sul, Egito, Israel, Resto do Médio Oriente e África (MEA) como parte do Médio Oriente e África (MEA), Brasil, Argentina e Resto da América do Sul como parte da América do Sul.

North America dominates the global biosimilar market because of the strong base of healthcare facilities, availability of reimbursements, rising geriatric population, high healthcare spending combined with the onset of COVID-19 pandemic and rising number of research activities in this region.  

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, ever-rising geriatric population base and the growing demand for quality healthcare in the region.

 The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global biosimilar market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for Biosimilar market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Biosimilar market. The data is available for historic period 2015-2020.

Competitive Landscape and Global Biosimilar Market Share Analysis

The global biosimilar market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global biosimilar market.

Some of the major players operating in the global biosimilar market are:

• Novartis AG (Switzerland)
•  Orion Pharma AB (Sweden)
•  Pfizer Inc. (U.S.)
• Samsung Bioepis. (South Korea)
•  Coherus BioSciences, Inc. (U.S.)
•  Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
•  Takeda Pharmaceutical Company Limited. (Japan)
•  Bristol-Myers Squibb Company (U.S.)
•  Merck KGaA (Germany)
•  Teva Pharmaceutical Industries Ltd. (U.S.)
•  Biocon. (India)
•  Bayer AG (Germany)
•  AbbVie Inc. (U.S.)
•  Allergan (Ireland)
•  Dr. Reddy’s Laboratories Ltd. (India)
•  Boehringer Ingelheim International GmbH. (Germany)
•  Biogen (U.S.)

SKU-12434